Successful coronary interventions performed with argatroban anticoagulation in patients with Heparin-Induced Thrombocytopenia and Thrombosis Syndrome

Journal of Invasive Cardiology

Volumn 8, Issue 9, 1996, Pages 410-417

  Lewis, Bruce E ^a   Ferguson, James J ^b   Grassman, Eric D ^b   Fareed, Jawed ^b   Walenga, Jeanine ^b   Joffrion, James L ^b   Wrona, Laura ^b   Johnson, Sarah A ^b   Schwarz Jr , Richard P ^b   McKiernan, Thomas ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b NONE

Author keywords

Argatroban; HITTS

Indexed keywords

EID: 0001359334     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New Engl J Med 1995;332:1330-1335.
2. Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaron (Org 10172). Thromb Haemost 1993;70:554-561.
3. Chong BH, Grace CS, Rozenberg ML. Heparin-induced thrombocytopenia: Effect of heparin platelet antibody on platelets. Br J Haematol 1981;49:531-540.
4. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin associated thrombocytopenia: The antibody is not heparin specific. Thromb Haemost 1992;67:547-549.
5. Adelman B, Sobel M, Fujimura Y, et al. Heparin-associated thrombocytopenia; Observations on the mechanism of platelet aggregation. J Lab Clin Med 1989;113:204-210.
6. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988;72:925-930.
7. Chong BH, Castaldi PA, Berndt M. Heparin-induced thrombocytopenia: Effects of rabbit IgG and FAB and FC fragments on antibody-heparin-platelet interaction. Thromb Res 1989;55:291-295.
8. Kelton JG, Smith IW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-3239.
9. Greinacher A, Poetzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-251.
10. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexes with heparin or heparin bound endothelial cells. J Clin Invest 1994;93:81-88.
11. Gueinadheu A, Liebenhoff U, Kiefel V, et al. Heparin-associated thrombocytopenia: The effects of various intravenous IgG preparations on antibody mediated platelet activation. A possible new indication for high dose IV IgG. Thromb Haemost 1994;71:641-645.
12. Amiral J, Bridey E, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-96.
13. Walls JT, Curtis JJ, Silver D, Boley TM. Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 1990;108:686-693.
14. Wallis DE, Lewis BE, Pifarre R, Scanlon PJ. Active surveillance for heparin-induced thrombocytopenia on thromboembolism. Chest 1994;106:1205.
15. King DE, Kelton JG. Heparin-induced thrombocytopenia. Ann Intern Med 1984;100:535-540.
16. Nand S, Robinson J. Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol 1988;28:204-206.
17. Brady J, Riccio JA, Yumen OH, et al. Plasmapheresis: A therapeutic option in the management of heparin-associated thrombocytopenia with thrombosis. Am J Clin Pathiol 1991;96:394-397.
18. Bouvier JL, Leferre P, Villain P. Treatment of serious heparin-induced thrombocytopenia by plasma exchange: Report on four cases. Thrombosis Research 1988;51:335-336.
19. Manzand L, Yebra M, Vargas JA, et al. Plasmapheresis in heparin-induced thrombocytopenia and thrombosis. Stroke 1990;21:1236.
20. Vender JS, Matthew EB, Silverman IM, et al. Heparin-associated thrombocytopenia: Alternative managements. Anesth Analg 1986;65:520-522.
21. Krueger SK, Andres E, Weinand E. Thrombolysis in heparin-induced thrombocytopenia with thrombosis. Ann Int Med 1985;103:159.
22. Dieck JA, Rizo-Patron C, Unisa A, et al. A new manifestation and treatment alternative for heparin-induced thrombosis. Chest 1990;98:1524-1526.
23. Fiessinger JN, Aiach M, Roncato M, et al. Critical ischemia during heparin-induced thrombocytopenia: Treatment by intra-arterial streptokinase. Thromb Res 1984;33:235-238.
24. Cole CW, Fournier LM, Bormanis J. Heparin-associated thrombocytopenia and thrombosis: Optimal therapy with Ancrod. CJS 1990;33:207-210.
25. Demeus C, Ginsberg JS, Brill-Edwards P. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;78:2194-2197.
26. Walenga JM, Koza MJ, Pifarre R. Comparative studies of heparin analogues, recombinant TFPI, and thrombin inhibitors devoid of heparin-induced thrombocytopenia response (Abstr). Thromb Haemost 1995;73:970.
27. Schiele F, Villemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50:20-25.
28. Chamberlin JR, Lewis B, Leya F, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirulog. Can J Cardiol 1995;11:511-514.
29. Matsuo T, Kario K, Chikahira Y, et al. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992;82:627-629.
30. Chong BH, Grace CS, Rozenberg MC. Heparin-induced thrombocytopenia: Effect of heparin platelet antibody on platelets. Br J Haematol 1981;49:531-540.
31. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Circulation 1990;82:1193-1202.
32. Lewis BE, Iaffaldano R, McKiernan T, et al. Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Cathet Cardiovasc Diagn (in press).
33. Matsuo T, Yamahda T, Yamanashi T, Ryo R. Anticoagulant therapy with MD 805 of hemodialysis patients with heparin-induced thrombocytopenia. Thrombosis Research 1990;58:663-666.
34. Gravanis MB, Roubin GS. Histopathologic phenomena at the site of coronary angioplasty. Br Heart J 1987;20:477-485.
35. Potkin BN, Roberts WC. Effects of coronary angioplasty on atherosclerotic plaques and relation of plaque composition and arterial size to outcome. Am J Cardiol 1988;62:41-50.
36. Fourrier JL, Stankowiak C, Lablanche JM. Histopathology after rotational angioplasty of peripheral arteries in human beings (Abstr). J Am Coll Cardiol 1988;11:109.
37. Cines DB, Tomaski A, Tannenbaum E. Immune endothelial cell injury in heparin-associated thrombocytopenia. New Engl J Med 1987;316:581-589.
38. Lefemine AA. Complications of heparin-induced thrombocytopenia. Am Surg 1982;48:202-206.
39. Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution. J Vasc Surg 1986;4:522-528.